Foundational guide
Kisspeptin Dosage: Tier One Data Without a Tier One Product
Roughly 45 registered studies and 26 completed, sponsored by academic hospitals. The evidence tier is the highest on this site, and it still does not produce an authorised quantity.
The grading method applied across this site usually resolves quickly, because most compounds examined here top out at tier two: rodent work, sometimes a single group, no human data. Kisspeptin is the case that reaches the top of the scale, which makes it worth grading in detail rather than in summary.
Grading the record
| Phase | Studies | What it establishes |
|---|---|---|
| Phase 3 | 4 | Efficacy against a comparator in a defined population |
| Phase 2 | 9 | Signal and exposure range |
| Phase 1 | 11 | Tolerability and pharmacokinetics in humans |
| Not applicable | 20 | Mechanistic and observational work |
Roughly 26 of the 45 are recorded as completed, and the lead sponsors are academic rather than commercial. That combination, completed controlled human work with prespecified endpoints and no vendor interest in the outcome, is the strongest evidence position examined anywhere on this site outside the approved drugs.
Why a high tier still yields no authorised quantity
Evidence tier and regulatory authorisation are independent axes, and this compound separates them cleanly. The trials happened and reported. No regulator has approved a marketed product, so there is no label, no authorised quantity, and nobody accountable for a number.
A kisspeptin dosage chart therefore has genuinely strong source material and no authorised figure to restate. The correct form is a quantity paired with the study population and the endpoint it produced, which is checkable. A bare figure discards exactly the information that made the source worth citing.
One assumption the tier does not cover
A trial preparation is manufactured to a specification and assayed before it reaches a participant. Material sold as a research chemical under the same compound name is a different object analytically, and its labelled mass is an assertion rather than a measurement.
Tier one evidence about a characterised preparation says nothing about the contents of an unassayed vial. Those are two separate questions, and only the first has been answered.
Frequently asked questions
- What evidence tier does kisspeptin reach?
- Tier one. Controlled human studies with prespecified endpoints exist, roughly 26 of them completed, which is the highest tier reached by any compound examined on this site apart from the approved drugs.
- Does a high tier imply an authorised dose?
- No. Tier describes the quality of evidence. Authorisation is a separate act performed by a regulator, and it has not happened for this compound.
- Who sponsored the studies?
- Predominantly academic bodies: a named investigator and Massachusetts General Hospital hold the largest blocks, with Imperial College London and university hospitals elsewhere adding more.
- What endpoints were measured?
- Hormonal responses on the reproductive axis, principally luteinising hormone, in populations defined by endocrine diagnosis or fertility indication.
- Is research-chemical kisspeptin the same material as the trial preparation?
- Not demonstrably. A trial preparation is manufactured to a specification and assayed; research-chemical material carries a seller's claim about its labelled mass.
Limitations of the evidence
This page grades evidence and prints no administration guidance. Kisspeptin holds no marketing authorisation in any market, so no authorised quantity exists despite a substantial trial programme. The published human figures were established in defined patient groups with prespecified hormonal endpoints under clinical supervision, and they carry no authorisation outside those settings. Material sold as a research chemical is not the preparation used in those trials and carries no verified labelled mass. Nothing here describes or recommends human use.